Abstract:Introduction Current staging methods do not accurately predict clinical outcome of patients with chronic lymphocytic leukemia (CLL) especially in the new era of immunotherapy. Recent studies suggested that immune-related gene signature predicted survival in glioblastoma, breast cancer and colorectal cancer. However, none related studies have been elucidated in CLL. Here, we hypothesized that risk-prediction model integrated with the immune signature could serve as an effective prognostic indicator in CLL. This study aimed to identify reliable and distinct immune-associated fingerprints for robust classification and survival prediction in patients with CLL. Methods A total of 720 de novo CLL patients from multiple cohorts were enrolled with informed consents in the present study. LASSO Cox regression model was utilized to calculate immune-associated risk score ( I-score ) in R software. Principal Component Analysis (PCA) were performed to present the distribution of risk score. Moreover, the prognostic capability of the five immune-related fingerprints was demonstrated by PCR and ROC curve analysis with leave-one-out cross validation in the training set. Functional enrichment analyses of GO and KEGG in gene expression datasets were performed. Association between I-score and hallmark gene sets from the Molecular Signatures Database (MSigDB) were analyzed using GSEA software. Furthermore, preclinical experiments were conduct to examine the pathological mechanism of constitutive genes of I-score in CLL cell lines (MEC1, EHEB) and primary cells. Additionally, genomic regulatory network was displayed in Cytoscape software. Results In the present study, we performed a comprehensive analysis to dissect the immune-associated fingerprints in CLL. A total of 305 clinical annotated CLL patients and 56 healthy donors with gene expression data were obtained from three independent cohorts. Two gene sets (immune system process, M13664 and immune response, M19817) were extracted from the MSigDB and combined to integrate the immune-related gene set containing 322 genes. Illustrated in the volcano plots, differentiated expressed genes of CLL cells comparing with normal B cells were calculated by limma test (|Log 2 Fold Change|u003e1, p Then, we further investigate the association of the immuno-signature with clinical outcomes of CLL patients. By Lasso Cox regression analysis, the prognostic immune-related fingerprints were identified in the training set (Figure 2A). The risk score method was established: I-score = (-0.538)* CD3D expression+(-0.077)* CD83 expression+0.364* LAX1 expression+0.191* IL2RA expression+0.362* AIM2 expression, consisting of protective genes (CD3D, CD83) and risky genes (LAX1, IL2RA and AIM2; Figure 2B). Based on the median level of I-score as cut-off value, stratified high-risk patients were observed with significantly shorter overall survival compared with the low-risk group (Hazard Ratio, HR=5.493, p I-score as an independent prognosis biomarker in CLL patients. To reduce disparity of diverse populations, we evaluated I-score in two independent centers of US and Germany with the same formula. The prognostic value of the immune fingerprints were corroborated in the internal validation series (HR=2.200, p =0.023; Figure 3B) and validation series (HR=1.769, p =0.004; Figure 3C). Intriguingly, we also observed the significant correlation between high I-score and 17p13 deletion ( p =0.0316; Figure 3D), in accordance with patients9 inferior outcome. Moreover, functional enrichment analyses of differentiated expressed genes stratified by I-score indicated that immune related BCR signaling pathway contributed to pathogenesis of CLL (Figure 4). Conclusion To date, our study provides evidence for the first time that distinct immuno-related fingerprints predict survival in CLL. I-score is demonstrated as an efficient classification tool and robust method for prognosis evaluation, greatly facilitating risk stratification and individualized management of CLL patients. Disclosures No relevant conflicts of interest to declare.

A prognostic immune risk score for diffuse large B-cell lymphoma

An Immune Risk Score Predicts Survival of Patients with Diffuse Large B-cell Lymphoma

Prognostic Significance of Systemic Immune-Inflammation Index in Patients with Diffuse Large B-Cell Lymphoma.

Immune scoring model based on immune cell infiltration to predict prognosis in diffuse large B‐cell lymphoma

Tumor-Infiltrating Lymphocyte-Based Risk Score for Predicting Prognosis in Gastric Cancer.

Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma

Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma

A Concise Prognostic Score System for Diffuse Large B-cell Lymphoma: a Retrospective Study with Long-Term Follow-Up

Immunophenotypic Landscape and Prognosis-Related Mrna Signature in Diffuse Large B Cell Lymphoma

Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)

An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment

Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma

Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment

Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators

A predictive model based on immune related genes for DLBCL

A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study

Implication of immune cell signature of tumor microenvironment in diffuse large B‐cell lymphoma

Discovery Of A Novel Five Immune-Associated Fingerprints For Classification And Survival Prediction In Chronic Lymphocytic Leukemia

International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma

A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients